Triple threat: radiation plus Immuno-Chemo shows promise for lung cancer
NCT ID NCT07608159
First seen Jun 05, 2026 · Last updated Jun 18, 2026 · Updated 3 times
Summary
This study tests whether adding a special type of radiation (SF-SBRT) to the usual combination of immunotherapy (toripalimab) and chemotherapy helps people with stage II-III non-small cell lung cancer live longer without the cancer coming back. About 200 participants will be randomly assigned to receive either the triple therapy or the standard two-drug therapy before surgery. The main goal is to see if the new approach improves the chance of being cancer-free two years after treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SURGERY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.